Which adverse effect profile is most characteristic of centrally acting cholinesterase inhibitors used in Alzheimer disease?
Choose an answer, then check it.
Clinical Pharmacology · Neurologic Medications
Alzheimer Disease Medications
On this page 6 sections
In 30 seconds
No drug available today cures Alzheimer disease or halts the neurodegeneration driving it. Cholinesterase inhibitors (donepezil, rivastigmine, galantamine) boost a chemical messenger to modestly ease symptoms in mild-to-moderate disease. Memantine, a different mechanism, is added in moderate-to-severe disease. Newer anti-amyloid antibodies target the disease process itself but require strict eligibility testing and serious safety monitoring. Non-drug care — caregiver support, avoiding anticholinergic drugs, and managing behavior without antipsychotics whenever possible — matters just as much as any prescription.
The college version
The Cholinergic Hypothesis and Cholinesterase Inhibitors
Alzheimer disease destroys neurons that produce acetylcholine, a neurotransmitter essential for memory and learning. The cholinergic hypothesis holds that restoring acetylcholine can partially compensate for this loss, even though it does not address the amyloid plaques and neurofibrillary tangles driving the disease. Cholinesterase inhibitors block acetylcholinesterase, the enzyme that normally breaks down acetylcholine in the synapse, so more remains available to stimulate surviving receptors.
Three centrally acting agents are used: donepezil, rivastigmine, and galantamine. Donepezil is taken once daily across mild, moderate, and severe stages. Rivastigmine is notable for its transdermal patch, which delivers steadier drug levels and often causes fewer gastrointestinal effects than oral dosing while improving adherence. Galantamine also modulates nicotinic receptors, though its overall effect is comparable to the others.
The benefit is real but modest: these drugs can slow the apparent rate of decline in memory and daily function for a period of months, but none stop disease progression. Boosting acetylcholine also drives parasympathetic effects: nausea, diarrhea, anorexia, weight loss, and vivid dreams. More concerning are cardiac effects — excess vagal tone can cause bradycardia and syncope — so these drugs are used cautiously in patients with conduction disease (such as sick sinus syndrome) and in peptic ulcer disease, since increased gastric acid secretion can provoke bleeding.
Memantine
Memantine is an NMDA-receptor antagonist. Chronic overactivation of NMDA glutamate receptors is thought to contribute to excitotoxicity, in which excessive calcium influx damages and kills neurons. Memantine partially blocks these receptors, dampening pathologic overstimulation while still permitting normal signaling needed for learning.
Memantine is reserved for moderate-to-severe disease and is frequently combined with a cholinesterase inhibitor, since the two act by unrelated mechanisms and may be complementary. It is generally well tolerated; the main issues are dizziness and confusion. Because it is cleared largely by the kidneys, its dose must be adjusted in renal impairment to avoid accumulation and toxicity.
Anti-Amyloid Monoclonal Antibodies
This newest class marks a shift from symptom management toward disease modification. These antibodies bind beta-amyloid protein, promoting its clearance, and are the first agents shown to slow, rather than merely mask, functional decline in early disease.
Their use carries important constraints. Before starting therapy, clinicians must confirm amyloid pathology, typically through specialized imaging or cerebrospinal fluid testing, since these drugs are indicated only for symptoms actually attributable to amyloid-related disease. Administration requires periodic intravenous infusion in a monitored setting. The signature safety concern is amyloid-related imaging abnormalities, a spectrum of brain swelling or microhemorrhage seen on MRI that requires scheduled surveillance imaging throughout treatment, with dose interruption if abnormalities appear.
The Bigger Picture: Non-Drug Care
Because pharmacologic options remain limited, non-drug strategies carry equal weight in comprehensive care. Caregiver education and support reduce burnout and improve quality of life. Minimizing anticholinergic burden from other medications is essential, since these drugs oppose the cholinergic strategy and worsen confusion. Behavioral symptoms of dementia, such as agitation, should be addressed first with non-pharmacologic approaches: environmental modification, structured routines, and redirection. Antipsychotics carry a boxed warning for increased mortality in older adults with dementia-related psychosis and should be reserved for situations where non-drug measures have failed and safety is at risk.
Eli explains
The same idea, in plain words
Explain it like I’m 10
Imagine your brain has tiny messengers that carry notes between neurons so you can remember things. In Alzheimer disease, the mailboxes for one kind of note (acetylcholine) start breaking down, so messages get lost. Some medicines slow down the mail truck that would normally take the note away, giving it more time to be read — that's what donepezil, rivastigmine, and galantamine do. Memantine works like a volume knob turned down on a different, noisy signal that was damaging brain cells. Neither fixes the broken mailboxes permanently — they just help things work a little better for a while. The newest medicines act like cleanup crews sent to remove sticky gunk called amyloid that clogs the brain — but doctors first must prove the gunk is really there, and they check the brain with scans regularly to catch swelling or bleeding. Just as important as any medicine is how people around a person with Alzheimer disease help them stay calm, safe, and comfortable every day.
Check yourself
2 review questions from the chapter. Try each one, then open the answer.
A patient with Alzheimer disease also has sick sinus syndrome. Why might a prescriber be cautious about starting a cholinesterase inhibitor, and what should be monitored?
Show answer
Cholinesterase inhibitors can slow heart rate further and cause fainting.
Sick sinus syndrome means the heart's natural pacemaker is already unreliable, and boosting acetylcholine can push heart rate down further or trigger fainting (syncope), so the prescriber weighs the modest cognitive benefit against real cardiac risk and monitors heart rate and for dizziness or fainting.
A family asks why an anti-amyloid antibody cannot simply be started as soon as their relative shows memory problems. What two requirements explain the delay?
Show answer
Confirmed amyloid pathology and a facility able to give infusions with imaging follow-up.
These antibodies only help memory problems actually caused by amyloid buildup, so testing (imaging or spinal fluid analysis) must confirm that pathology first, and because the drug is infused and carries a risk of brain swelling or bleeding, the patient needs regular follow-up MRI scans to catch amyloid-related imaging abnormalities early.
Quick check
3 questions here. Answers stay hidden until you check.
Memantine's mechanism of action is best described as:
Choose an answer, then check it.
Which formulation feature is specifically associated with rivastigmine?
Choose an answer, then check it.
Study tools & related lessonsRelated
Educational content only. It is not medical, legal or professional advice. Found an error? Tell us.